Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: incobotulinumtoxinA (Xeomin) Clear all
Completed Phase 4 Interventional Results available

Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis

NCT04148872
View directory record Official record
Conditions
Synkinesis
Interventions
Neuromuscular Retraining Therapy (4 months), Chemodenervation (4 months), Neuromuscular Retraining + Chemodenervation
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

NCT04763265
View directory record Official record
Conditions
Frown Lines
Interventions
Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics"
Biological
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Santa Monica, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 4, 2026, 9:36 AM EDT
Terminated No phase listed Observational

Longitudinal Evaluation and Real-world Evidence of NT201

NCT05222607
View directory record Official record
Conditions
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Terminated Phase 2 Interventional Results available

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

NCT04965311
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity

NCT00945295
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
Botulinum toxin type A, BoNT-A, Rehabilitation Therapy
Drug · Other
Lead sponsor
JoAnn Harnar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 4, 2026, 9:36 AM EDT
Recruiting Phase 2 Interventional

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT03571334
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
IncobotulinumtoxinA (Xeomin®, Merz) (INA), Normal saline
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

NCT04247074
View directory record Official record
Conditions
Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)
Interventions
botulinum toxin neuromodulator, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
11
States / cities
Encino, California • Santa Monica, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Moderate to Severe Glabellar Lines

NCT04249583
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin, Placebo
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
13
States / cities
Manhattan Beach, California • Vista, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

NCT00407030
View directory record Official record
Conditions
Cervical Dystonia
Interventions
incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 4, 2026, 9:36 AM EDT
Recruiting Phase 4 Interventional

Xeomin® and Gait Related Mobility After Stroke

NCT04908423
View directory record Official record
Conditions
Stroke
Interventions
Xeomin®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

NCT01603459
View directory record Official record
Conditions
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Plantar Fasciitis With Xeomin

NCT01678001
View directory record Official record
Conditions
Plantar Fascitis
Interventions
Xeomin
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 4, 2026, 9:36 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles

NCT02019004
View directory record Official record
Conditions
Wrinkles
Interventions
Onabotulinum Toxin A, Incobotulinum Toxin A
Drug
Lead sponsor
Northwestern University
Other
Eligibility
20 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Early BOTOX After Spinal Cord Injury

NCT06793683
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Bladder chemodenervation (Botox), Bladder Sham (Saline) Injection Procedure
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

NCT03985982
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 2 Interventional Results available

A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea

NCT01614743
View directory record Official record
Conditions
Rosacea
Interventions
IncobotulinumtoxinA, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 4, 2026, 9:36 AM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 4, 2026, 9:36 AM EDT
Recruiting Phase 2 Interventional

IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction

NCT07486830
View directory record Official record
Conditions
Provoked Vestibulodynia
Interventions
Incobotulinum Toxin A, Placebo
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404
View directory record Official record
Conditions
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

NCT06034288
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Xeomin 100 UNT Injection, Botox 100 UNT Injection
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 4, 2026, 9:36 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

NCT07122193
View directory record Official record
Conditions
Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents, incobotulinumtoxinA, Botulinum Toxins, Type A
Interventions
NT 201, NT 201 Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Scottsdale, Arizona • Encino, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 4, 2026, 9:36 AM EDT